NANO PRECISION MEDICAL - Key Persons
Mr. Mendelsohn has been involved in financing in the medical field, including several Al Mann companies such as MiniMed, MRG, and Advanced Bionics. He is a founder and, since its inception, has been a director for Second Sight Medical Products, a publicly traded company which developed and commercialized the world's first prosthetic retinal stimulator that restores some useful vision to the profoundly blind. He served as a director of MRG from its formation in 1998 until it was sold in 2001 to Medtronic, Inc. He served on the board of Advanced Bionics for many years until it was sold to Boston Scientific in 2004. He served as a director of the Alfred Mann Institute for Biomedical Engineering at USC from its inception in 1998 until after Al's death in 2016. During that time, he was a member of the 3-man committee that served as the CEO. He is a founder of Mastacopia, S.A., a start-up company which has developed a new and better method of breast cancer screening currently in testing at a Harvard University hospital.
Mr. Mendelsohn also is a founder and has served as Chairman of the Maestro Foundation since it was organized in 1983. The Maestro foundation is a leading non-profit musical philanthropic organization which hosts what is considered to be the nation's premier chamber music series and has an active instrument lending program which lends approximately 100 professional-level string instruments and bows to young, career-bound classical musicians. Mr. Mendelsohn holds a Bachelor's Degree with honors from UCLA and holds a JD from Loyola University School of Law.
Job Titles:
- Chairman
- Chief Executive Officer
- Co - Founder
Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.
Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.
Dr. Mendelsohn has served as a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF's Graduate Division Alumni Association, and is currently a board member of the Maestro Foundation.
Before joining NPM, Ms. Makes served as an independent consultant for primarily private medical device companies since July 2017. Prior to that, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, a global medical device company dedicated to bringing innovative and clinically proven applications to the aesthetic marketplace, which was acquired by Sientra in July 2017. From 2006 to 2011 Ms. Makes served in the same roles for AGA Medical, a medical device company specializing in the treatment of cardiovascular defects, which was acquired by St. Jude Medical, another medical device company, in November 2010. Prior to AGA Medical, from 1999 to 2006, Ms. Makes served in a variety of executive positions, including as Chief Financial Officer, for Nektar Therapeutics (formerly Inhale Therapeutics), a biopharmaceutical company. Ms. Makes also served as Chief Financial Officer for Oravax, a biopharmaceutical company, from 1998 to 1999 and for Haemonetics Corp, a company specializing in the management of blood supplies, from 1995 to 1998.
Since December 2019, Ms. Makes has also been a member of the board of directors of Mind Medicine (MindMed) Inc., a publicly traded neuro-pharmaceutical company, where Ms. Makes serves on the Audit Committee as chair, and the Compensation and Nominating and Governance Committees. Since 2020, Ms. Makes also serves as a board director of Aziyo Biologics, a commercial-stage regenerative medicine company. Brigid chairs both the Audit and Nominating Corporate Governance committees for Aziyo. Since June 2021, Ms. Makes has served as a board director and chair of the Audit Committee for Quantum-Si, Inc., a life science tools company focused on commercializing a unique protein sequencing platform. Ms. Makes holds a Bachelor of Commerce degree in Finance and International from McGill University and an M.B.A. from Bentley University.
Dan Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.
Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three firstin-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin's Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves as a Director at multiple public and private life sciences companies including Biocon Limited, Castle Biosciences, Equillium Inc, Intercept Pharmaceuticals, Biolinq, IQHQ, DelNova, Liquid Grids, Prosciento, Renova Therapeutics, Sensulin and Synedgen. He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego's Rady School of Management's Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board, the Arctic Aurora Life Science Advisory Board and is an advisor to Patricia Industries (a part of Investor AB).
Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Dr. Baker was also a vice president of Northrop Grumman for 16 years, overseeing a division with $1 billion in annual sales. Dr. Baker has continued to advise Nano Precision Medical in intellectual property, compensation, capitalization, and operation issues.
Don is a science-based business leader with over 35 years of experience in the biopharmaceutical industry and a broad background in leadership across a wide range of technologies and disease areas. Don has held director level positions in quality assurance/control and regulatory affairs (Rhone-Poulenc Rorer and Cephalon); and drug development, sales, commercial and business development (AstraZeneca). He also served as AstraZeneca's observer on the Board of Directors for PhaseBio (2014-2018) and Nano Precision Medical (2015-2019). At AstraZeneca (AZ), he was Executive Director Business Development and Early Asset (pre-Phase 3) Commercial lead for Cardiovascular, Renal and Metabolic Disease where he co-led the $2.7B acquisition of LOKELMA (hyperkalemia) from ZS Pharma and the $1.2B licensing and co-commercialization deal for TC-5214 (major depressive disorder) with Targacept. On the divestment side, Don was also co-lead on multiple projects including the ZOLADEX implant (cancer), Earlier in his career, he was the US commercial head for key brands including TOPROL-XL (heart failure, hypertension, angina); ATACAND (hypertension); ONGLYZA (diabetes); FARXIGA (diabetes); SEROQUEL (bipolar disorder) and ABRAXANE (cancer).
Mr. Dwyer is a graduate of the University of Central Connecticut (chemistry/biology) and Temple University Fox School of Business (M.B.A.).
Gary T. Elliott brings 35 years in the industry including Vice or Executive Vice President Product Development and Technical Operations with Salmedix, Adventrx, HuyaBioscience, Ribi Immunochem and Sr. Director at Corixa. His experience has been built upon a formal didactive background of Pharmacy, Clinical Pharmacology and Medicinal Chemistry. Dr Elliott has had considerable interaction over the years with US, Canadian and European drug and biologics regulatory authorities, authoring and supervising compilation of many regulatory filings (e.g. INDs, NDAs, annual reports, end of Phase 2, Phase 3 and NDA, CMC, preclinical safety and clinical technical documents) and experience organizing participating and leading associated face to face and telephonic Type A, B and C meetings with regulatory authorities. Dr. Elliott is consequently well versed in preclinical pharmacology, drug safety, CMC, bioanalytical FDA and ICH regulatory guidances and Phase Appropriate Drug Development Strategy as applied in US, EU, Canadian and Australian theatres.
Gary brings integrated technical expertise in formulation, analytical, medicinal chemistry and experience and expertise in Natural Products/plant-derived Drug Substance and Drug Product Development, bioanalytical method development and in vitro and in vivo biological testing. Gary has additionally designed and supervised pharmacology, toxicology and clinical programs in multiple therapeutic areas including but not limited to infectious disease, immunology, oncology and cardiology. Since the successful sale of Salmedix, Gary has served as a consultant to the industry and is currently a Lead consultant and Partner with Pharmaceutical Advisors LLC and President of Galenic Strategies LLC.
Job Titles:
- Chairman of the Board
- Director
- Chairman, President and Chief Executive Officer of Williams International Co
Gregg Williams is the Chairman, President and Chief Executive Officer of Williams International Co., LLC, the world's leading producer of small fanjet engines for business jet and defense applications. Prior to his current assignment at Williams International, Mr. Williams held several key managerial positions within the company including serving as its President & Chief Operating Officer, Vice President, Advanced Technology, Director, Program Management and Director, Engineering. He received a Bachelor of Science degree in mechanical engineering from the University of Utah and holds numerous patents related to gas turbine engines, turbo machinery, rocket engines and engine control systems.
Mr. Williams is also the Chairman of the board and largest shareholder of Second Sight Medical Products, a publicly traded company (NASDAQ: EYES) dedicated to defeating blindness by developing and commercializing implantable visual prostheses. In addition, Mr. Williams is Chairman and majority owner of Ramos Arizpe Manufacturing an automotive engine parts manufacturing company located in Mexico. He also serves on the Board of Directors of the General Aviation Manufacturers Association, is a past member of the Young Presidents Organization, and a former member of Henry Ford Health System's board of trustees. Gregg is an active pilot with multiengine, instrument and seaplane ratings.
Job Titles:
- Professor of Economics at MIT
Jerry A. Hausman is the MacDonald Professor of Economics at MIT. Professor Hausman received a D.Phil. (Ph.D.) degree from Oxford University where he was a Marshall Scholar. He has been a faculty member at MIT for 45 years. Professor Hausman received the John Bates Clark Award from the American Economics Association in 1985 for the most outstanding contributions to economics by an economist under 40 years of age. He also received the Frisch Medal from the Econometric Society and the Biennial Medal of the Modeling and Simulation Society of Australia and New Zealand. In 2013 he was named a Distinguished Fellow of the American Economic Association. Professor Hausman's research concentrates on econometrics and applied microeconomics. His applied research has been in demand for differentiated products, telecommunications, regulation, the effects of taxation on the economy, and industrial organization. More information available on his CV.
Dr. Porter has over 20 years of experience in developing medicines for metabolic diseases with a focus on bringing innovative therapies to patients with high unmet need. Before joining NPM she served as CMO, Metabolic Diseases for Eiger Biopharmaceuticals where she led clinical development for the orphan diseases postbariatric hypoglycemia and Hutchinson-Gilford Progeria Syndrome resulting in FDA breakthrough therapy designation for both programs. She has previously served as CMO for Dance BioPharma (now Aerami Therapeutics) and Vice President, Medical Development for Amylin Pharmaceuticals where she led the R&D efforts for the Amylin-Lilly Alliance culminating in the approval of the GLP-1 agonist Bydureon, the 1st once weekly treatment for Type 2 diabetes. Prior to joining Amylin, Dr. Porter held progressively increasing leadership positions at GlaxoSmithKline Pharmaceuticals with responsibilities for the clinical strategy for Avandia and early obesity compounds and Associate Medical Director for Zeneca Pharmaceuticals. Dr. Porter is currently a board member of Viacyte, Inc.
Dr. Porter earned a BS in Biology from the College of William & Mary, an MD from Duke University and completed fellowship training in Endocrinology and Hypertension at Brigham and Women's Hospital.
During his 20 year tenure at Amylin, Orville Kolterman, M.D. was instrumental in the development of first-in-class diabetes medicines, including SYMLIN, and BYETTA, BYDUREON and Myalept injections. Prior to his appointment as Senior Vice President & Chief Medical Officer, Dr. Kolterman held leadership roles in the regulatory, research, development, clinical and medical affairs departments, many of which were officer-level positions. Before Amylin, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Dr. Kolterman has served as a board member for the American Diabetes Association (ADA) Research Foundation and is a past President of the California Affiliate of the ADA. He has held the role of Adjunct Professor of Medicine at the University of California, San Diego for over 20 years. Dr. Kolterman earned his medical degree from Stanford University School of Medicine. Dr. Kolterman currently serves as the Chief Medical Officer for Pendulum Therapeutics.
Mr. Le brings over 35 years of manufacturing, quality, and overall operations experience with devices and complex drug-device combination products. From 2011 to March 2020, Mr. Le was the Chief Technical Operations Officer for Dance Biopharm - a leader in aqueous respiratory therapy delivery with Drug and Device combination products - he built the Operations, Quality Systems, Manufacturing, Supply Chain, Product Development, Formulation, and IT. From 2009 to 2011, Mr. Le was the Chief Operating Officer for Avid Bio services, Inc., a leading contract manufacturing organization that specializes in clinical trials and commercial distribution of monoclonal antibodies and recombinant proteins. From 2007 to 2009, Mr. Le served as the EVP Manufacturing and Quality for PrimaBiomed, a cell therapy company, and as a consultant for several drug/device companies. From 2001 to 2007, Mr. Le was Senior Vice President of Operations, Product Development, Quality, and Regulatory Affairs for Nektar Therapeutics, a biopharmaceutical company, where he led the commercial formulation and device manufacturing for Exubera. From 1999 to 2001, he consulted for multiple large pharmaceutical and medical device companies (Abbott, Medtronic, Baxter, Dow Chemical) specializing in Due-diligence, Operation Effectiveness, and PAI readiness. From 1981 to 1999, Mr. Le was employed for a division of Johnson & Johnson, as the Worldwide Vice-President of Regulatory Compliance and Quality Systems. His work at Johnson & Johnson included 10+ years in operations, regulatory affairs, product development, manufacturing, and quality for ophthalmic products such as cataract devices and implants and drug products for ophthalmic surgery procedures.
Mr. Le has a B.S. in mechanical engineering, M.B.A. in Management, and completed numerous executive leadership training programs, including World Class Manufacturing at Duke University, Executive Management at Harvard University, and a QSR trainer at AAMI/FDA.